SCHEMBL200699

SCHEMBL200699

COC(=O)c1ccnc(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.62
KDM6B O15054 1/20 0.62
KDM5C P41229 1/20 0.62
KDM4C Q9H3R0 1/20 0.62
KDM2A Q9Y2K7 1/20 0.62
KDM3A Q9Y4C1 1/20 0.62
ALOX15 P16050 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
JMJD6 Q6NYC1 1/20 0.54
CA12 O43570 3/20 0.53
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA7 P43166 3/20 0.53
CA9 Q16790 3/20 0.53
CA14 Q9ULX7 3/20 0.53
XDH P47989 2/20 0.53
HTT P42858 2/20 0.50
HPGD P15428 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70279 0.82 KDM4E (0.86) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL29894587 0.82 KDM4E (0.86) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL1759313 0.81 KDM4E (0.58) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL30378954 0.81 KDM4E (0.58) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL30065796 0.81 KDM4E (0.62) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL1180311 0.81 KDM4E (0.62) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL6514670 0.81 KDM4E (0.83) KDM4EKDM6BKDM5CKDM4CKDM2A
Hydrochloric Acid SCHEMBL6504834 0.81 KDM4E (0.83) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL31320056 0.81 KDM4E (0.62) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL70350 0.81 KDM4E (0.62) KDM4EKDM6BKDM5CKDM4CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4209467-A COBALT COMPLEX CATALYST DAICEL LTD. (JP) 1980-06-24 US claimed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 EP disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 US disclosed
WO-2024073475-A9 CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) 2025-04-24 WO disclosed
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2024-12-12 US disclosed
WO-2024073475-A1 CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-29 US disclosed
CN-117377665-A PARP7 inhibitor and application thereof 北京华森英诺生物科技有限公司 2024-01-09 CN disclosed
US-20230416238-A1 N-[(1,3-BENZOXAZOL-2-YL)-HETEROCYCLE]AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-12-28 US disclosed
US-20230365507-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2023-11-16 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed
US-6872731-B2 Imidazo-pyridine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LTD. (GB) 2005-03-29 US disclosed
EP-1235827-B1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2004-07-07 EP disclosed
US-20020188000-A1 Imidazo-pyridine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2002-12-12 US disclosed
EP-1235827-A2 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2002-09-04 EP disclosed
WO-2001038326-A2 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2001-05-31 WO disclosed
US-4968803-A FLUORINE AS OXIDANT ALLIED-SIGNAL INC. (US) 1990-11-06 US disclosed
US-4209467-A COBALT COMPLEX CATALYST DAICEL LTD. (JP) 1980-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 KDM4E 306/4885KDM6B 239/4885KDM5C 23/4885
US-20020188000-A1 Imidazo-pyridine derivatives as ligands for gaba receptors GABRA3, GABRA2, GABRA1 KDM4E 2843/4885KDM6B 3953/4885KDM5C 3322/4885
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 KDM4E 3223/4885KDM6B 2551/4885KDM5C 3828/4885
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF EGFR, ERBB2, ERBB3 KDM4E 169/4885KDM6B 119/4885KDM5C 104/4885
US-20230416238-A1 N-[(1,3-BENZOXAZOL-2-YL)-HETEROCYCLE]AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION CYP2E1, HAVCR2, CYP4X1 KDM4E 1682/4885KDM6B 1778/4885KDM5C 1910/4885
US-20230365507-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 KDM4E 3223/4885KDM6B 2551/4885KDM5C 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.